Abstract
As in all malignant disease an accurate characterization of the tumour is mandatory to predict the prognosis and to guide the treatment. Most urologists and oncologists feel today that the malignancy grade is the most important parameter in the evaluation of tumour aggressiveness. Therapeutic decisions also imply assessment of the tumour extent.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
W.F. Whitmore, Jr., Hormone therapy in prostatic cancer, Amer. J. Med. 21:697 (1956).
W.J. Catalona and W.W. Scott, Carcinoma of the prostate: A review, J. Urol. 119:1 (1978).
R.J. Correa, R.G Anderson, R.P. Gibbons, and J. Tate Mason, Latent carcinoma of the prostate — why the controversy?, J. Urol. 111:644 (1974).
P.F. Denoix, Presentation d’une nomenclature classification des cancers basée sur un atlas, Acta Unio Internat. contra cancrum 9:769 (1953).
H.J. Jewett, Significance of the palpable prostatic nodule, J.A.M.A. 160:838 (1956).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Springer Science+Business Media New York
About this chapter
Cite this chapter
Andersson, L. (1983). Prostatic Cancer Staging — An Overview. In: Pavone-Macaluso, M., Smith, P.H. (eds) Cancer of the Prostate and Kidney. NATO Advanced Science Institutes Series, vol 53. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-4349-3_22
Download citation
DOI: https://doi.org/10.1007/978-1-4684-4349-3_22
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-4351-6
Online ISBN: 978-1-4684-4349-3
eBook Packages: Springer Book Archive